⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

August 1, 2025

Supplementary Figure 2 from A PD-L1/CD3 Bispecific Antibody Enhances the Antitumor Effects of Regorafenib against Colon Cancer

Izuchukwu F. Okpalanwaka Elizabeth A. Daugherity Amanda L. McCormick Trevor S. Anderson Savanna L. Smith Caryn Lawrence Duke Appiah Devin B. Lowe

View at Publisher

Ask AI

Bookmark

Share

Key Points

MAIN FINDING: PD-L1 expression does not significantly change with regorafenib treatment in colon cancer.
KEY EVIDENCE: Data from Supplementary Figure 2 illustrate stable PD-L1 levels post-regorafenib exposure.
APPROACH: The research involved assessing PD-L1 expression levels in response to bispecific antibody and regorafenib.
SIGNIFICANCE: Understanding PD-L1 dynamics can inform future therapies for enhancing antitumor effects in colon cancer.

Implication

Findings show PD-L1 expression remains unchanged after regorafenib treatment in colon cancer, suggesting potential treatment strategies.

Abstract

Supplementary Figure 2 details PD-L1 expression is not observably altered following REG exposure.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Okpalanwaka et al. (2025) studied this question.

synapsesocial.com/papers/689a0c72e6551bb0af8d020c https://doi.org/10.1158/1535-7163.29760650

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure 1 from A PD-L1/CD3 Bispecific Antibody Enhances the Antitumor Effects of Regorafenib against Colon Cancer2025
2Supplementary Figure 3 from A PD-L1/CD3 Bispecific Antibody Enhances the Antitumor Effects of Regorafenib against Colon Cancer2025
3Supplementary Figure 4 from A PD-L1/CD3 Bispecific Antibody Enhances the Antitumor Effects of Regorafenib against Colon Cancer2025
4Supplementary Figure 9 from A PD-L1/CD3 Bispecific Antibody Enhances the Antitumor Effects of Regorafenib against Colon Cancer2025
5Supplementary Figure 8 from A PD-L1/CD3 Bispecific Antibody Enhances the Antitumor Effects of Regorafenib against Colon Cancer2025

Supplementary Figure 5 from A PD-L1/CD3 Bispecific Antibody Enhances the Antitumor Effects of Regorafenib against Colon Cancer2025
Supplementary Figure 6 from A PD-L1/CD3 Bispecific Antibody Enhances the Antitumor Effects of Regorafenib against Colon Cancer2025
Supplementary Figure 7 from A PD-L1/CD3 Bispecific Antibody Enhances the Antitumor Effects of Regorafenib against Colon Cancer2025